These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 28125507)

  • 1. Behavioural effects of novel multitarget anticholinesterasic derivatives in Alzheimer's disease.
    Giménez-Llort L; Ratia M; Pérez B; Camps P; Muñoz-Torrero D; Badia A; Clos MV
    Behav Pharmacol; 2017 Apr; 28(2 and 3-Spec Issue):124-131. PubMed ID: 28125507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of huprine X on β-amyloid, synaptophysin and α7 neuronal nicotinic acetylcholine receptors in the brain of 3xTg-AD and APPswe transgenic mice.
    Hedberg MM; Clos MV; Ratia M; Gonzalez D; Lithner CU; Camps P; Muñoz-Torrero D; Badia A; Giménez-Llort L; Nordberg A
    Neurodegener Dis; 2010; 7(6):379-88. PubMed ID: 20689242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Donepezil: an important prototype to the design of new drug candidates for Alzheimer's disease.
    Rodrigues Simões MC; Dias Viegas FP; Moreira MS; de Freitas Silva M; Riquiel MM; da Rosa PM; Castelli MR; dos Santos MH; Soares MG; Viegas C
    Mini Rev Med Chem; 2014 Jan; 14(1):2-19. PubMed ID: 24251806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Huprine X is a novel high-affinity inhibitor of acetylcholinesterase that is of interest for treatment of Alzheimer's disease.
    Camps P; Cusack B; Mallender WD; El Achab RE; Morral J; Muñoz-Torrero D; Rosenberry TL
    Mol Pharmacol; 2000 Feb; 57(2):409-17. PubMed ID: 10648652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AVCRI104P3, a novel multitarget compound with cognition-enhancing and anxiolytic activities: studies in cognitively poor middle-aged mice.
    Giménez-Llort L; Ratia M; Pérez B; Camps P; Muñoz-Torrero D; Badia A; Clos MV
    Behav Brain Res; 2015 Jun; 286():97-103. PubMed ID: 25732954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Huprine-tacrine heterodimers as anti-amyloidogenic compounds of potential interest against Alzheimer's and prion diseases.
    Galdeano C; Viayna E; Sola I; Formosa X; Camps P; Badia A; Clos MV; Relat J; Ratia M; Bartolini M; Mancini F; Andrisano V; Salmona M; Minguillón C; González-Muñoz GC; Rodríguez-Franco MI; Bidon-Chanal A; Luque FJ; Muñoz-Torrero D
    J Med Chem; 2012 Jan; 55(2):661-9. PubMed ID: 22185619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel Levetiracetam Derivatives That Are Effective against the Alzheimer-like Phenotype in Mice: Synthesis, in Vitro, ex Vivo, and in Vivo Efficacy Studies.
    Sola I; Aso E; Frattini D; López-González I; Espargaró A; Sabaté R; Di Pietro O; Luque FJ; Clos MV; Ferrer I; Muñoz-Torrero D
    J Med Chem; 2015 Aug; 58(15):6018-32. PubMed ID: 26181606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tacrine derivatives and Alzheimer's disease.
    Tumiatti V; Minarini A; Bolognesi ML; Milelli A; Rosini M; Melchiorre C
    Curr Med Chem; 2010; 17(17):1825-38. PubMed ID: 20345341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel tacrine analogs as potential cholinesterase inhibitors in Alzheimer's disease.
    El-Malah A; Gedawy EM; Kassab AE; Salam RM
    Arch Pharm (Weinheim); 2014 Feb; 347(2):96-103. PubMed ID: 24343873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potent Acetylcholinesterase Inhibitors: Potential Drugs for Alzheimer's Disease.
    Akıncıoğlu H; Gülçin İ
    Mini Rev Med Chem; 2020; 20(8):703-715. PubMed ID: 31902355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).
    McHardy SF; Wang HL; McCowen SV; Valdez MC
    Expert Opin Ther Pat; 2017 Apr; 27(4):455-476. PubMed ID: 27967267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rational design, synthesis and biological screening of triazine-triazolopyrimidine hybrids as multitarget anti-Alzheimer agents.
    Jameel E; Meena P; Maqbool M; Kumar J; Ahmed W; Mumtazuddin S; Tiwari M; Hoda N; Jayaram B
    Eur J Med Chem; 2017 Aug; 136():36-51. PubMed ID: 28478343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Huprine X and huperzine A improve cognition and regulate some neurochemical processes related with Alzheimer's disease in triple transgenic mice (3xTg-AD).
    Ratia M; Giménez-Llort L; Camps P; Muñoz-Torrero D; Pérez B; Clos MV; Badia A
    Neurodegener Dis; 2013; 11(3):129-40. PubMed ID: 22626981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis and multitarget biological profiling of second-generation anti-Alzheimer rhein-huprine hybrids.
    Pérez-Areales FJ; Betari N; Viayna A; Pont C; Espargaró A; Bartolini M; De Simone A; Rinaldi Alvarenga JF; Pérez B; Sabate R; Lamuela-Raventós RM; Andrisano V; Luque FJ; Muñoz-Torrero D
    Future Med Chem; 2017 Jun; 9(10):965-981. PubMed ID: 28632395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual binding site acetylcholinesterase inhibitors: potential new disease-modifying agents for AD.
    del Monte-Millán M; García-Palomero E; Valenzuela R; Usán P; de Austria C; Muñoz-Ruiz P; Rubio L; Dorronsoro I; Martínez A; Medina M
    J Mol Neurosci; 2006; 30(1-2):85-8. PubMed ID: 17192640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bis(9)-(-)-nor-meptazinol as a novel dual-binding AChEI potently ameliorates scopolamine-induced cognitive deficits in mice.
    Liu T; Xia Z; Zhang WW; Xu JR; Ge XX; Li J; Cui Y; Qiu ZB; Xu J; Xie Q; Wang H; Chen HZ
    Pharmacol Biochem Behav; 2013 Mar; 104():138-43. PubMed ID: 23262302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel bis-(-)-nor-meptazinol derivatives act as dual binding site AChE inhibitors with metal-complexing property.
    Zheng W; Li J; Qiu Z; Xia Z; Li W; Yu L; Chen H; Chen J; Chen Y; Hu Z; Zhou W; Shao B; Cui Y; Xie Q; Chen H
    Toxicol Appl Pharmacol; 2012 Oct; 264(1):65-72. PubMed ID: 22842334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel huprine derivatives with inhibitory activity toward β-amyloid aggregation and formation as disease-modifying anti-Alzheimer drug candidates.
    Viayna E; Gómez T; Galdeano C; Ramírez L; Ratia M; Badia A; Clos MV; Verdaguer E; Junyent F; Camins A; Pallàs M; Bartolini M; Mancini F; Andrisano V; Arce MP; Rodríguez-Franco MI; Bidon-Chanal A; Luque FJ; Camps P; Muñoz-Torrero D
    ChemMedChem; 2010 Nov; 5(11):1855-70. PubMed ID: 20859987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel Tacrine-Benzofuran Hybrids as Potent Multitarget-Directed Ligands for the Treatment of Alzheimer's Disease: Design, Synthesis, Biological Evaluation, and X-ray Crystallography.
    Zha X; Lamba D; Zhang L; Lou Y; Xu C; Kang D; Chen L; Xu Y; Zhang L; De Simone A; Samez S; Pesaresi A; Stojan J; Lopez MG; Egea J; Andrisano V; Bartolini M
    J Med Chem; 2016 Jan; 59(1):114-31. PubMed ID: 26632651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dimeric Tacrine(10)-hupyridone as a Multitarget-Directed Ligand To Treat Alzheimer's Disease.
    Xuan Z; Gu X; Yan S; Xie Y; Zhou Y; Zhang H; Jin H; Hu S; Mak MSH; Zhou D; Keung Tsim KW; Carlier PR; Han Y; Cui W
    ACS Chem Neurosci; 2021 Jul; 12(13):2462-2477. PubMed ID: 34156230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.